Nervous System News and Research

Latest Nervous System News and Research

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

International Panel Revises "McDonald Criteria" for Diagnosing MS -- Use of new data should speed diagnosis -- Publication coincides with MS Awareness Week

10 Mar 2011

Professor utilizes $300,000 N.Y. grant to study adult neural stem cells

Rensselaer Polytechnic Institute Assistant Professor of Biomedical Engineering Deanna Thompson is utilizing more than $300,000 in New York state funding as part of the state stem cell research program, NYSTEM, to study adult neural stem cells.

10 Mar 2011

CDH Proton Center expands treatment capacity

The CDH Proton Center, A ProCure Center, in suburban Chicago, is now able to treat a wider variety of cancer tumors with the opening of a treatment room with a gantry, a nearly 100-ton rotating steel wheel that allows the proton beam to be directed at the tumor from any angle.

10 Mar 2011

NextGen Group subsidiary completes commercial reorganization

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has completed a commercial reorganization. The restructuring, which is accompanied by new management appointments, is expected to help the company execute its strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

10 Mar 2011

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

The sensory cells in the retina of the mammalian eye convert light stimuli into electrical signals and transmit them via downstream interneurons to the retinal ganglion cells which, in turn, forward them to the brain. The interneurons are connected to each other in such a way that the individual ganglion cells receive visual information from a circular area of the visual field known as the receptive field.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb in the area of Alzheimer's disease and other neurodegenerative conditions.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

A study into the effects of Sanfilippo Syndrome type B (MPS III B) has found that the barrier responsible for protecting the brain from the entry of harmful blood-borne substances is structurally and functionally damaged by the devastating disease. University of South Florida researchers identified damage in specific brain structures involved in the pathology of MPS III B, one of four Sanfilippo syndromes, all of which are inherited diseases of metabolism.

9 Mar 2011

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

In the past few months, a slew of papers have indicated that the therapeutic potential of a promising type of stem cell, called induced pluripotent stem (iPS) cells, might be limited by reprogramming errors and genomic instability. iPS cells are engineered by reprogramming fully differentiated adult cells, often skin cells, back to a primitive, embryonic-like state.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

New report highlights wide range of hazardous air pollutants emitted from power plants

The American Lung Association today released Toxic Air: The Case for Cleaning Up Coal-fired Power Plants, a new report that documents the range of hazardous air pollutants emitted from power plants and the urgent need to clean them up to protect public health.

8 Mar 2011

Stroke survivors with atrial fibrillation may be at greater risk of developing Dementia

Stroke survivors who have an irregular heartbeat called atrial fibrillation may be at higher risk of developing dementia than stroke survivors who do not have the heart condition, according to research published in the March 8, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

8 Mar 2011

New insight into multiple sclerosis

Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis.

8 Mar 2011

Nervous System News and Research

Latest Nervous System News and Research

Novartis new MS treatment receives Notice of Compliance in Canada

Positive results from exenatide phase 2 study in patients with type 2 diabetes

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

Professor utilizes $300,000 N.Y. grant to study adult neural stem cells

CDH Proton Center expands treatment capacity

NextGen Group subsidiary completes commercial reorganization

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

USPTO grants new patent to Intellect's Alzheimer's vaccine

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

New report highlights wide range of hazardous air pollutants emitted from power plants

Stroke survivors with atrial fibrillation may be at greater risk of developing Dementia

New insight into multiple sclerosis

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in